Skip to main content
. Author manuscript; available in PMC: 2019 Feb 8.
Published in final edited form as: Nature. 2018 Aug 8;560(7718):382–386. doi: 10.1038/s41586-018-0392-8

Figure 2. The level of PD-L1 on circulating exosomes distinguishes patients with metastatic melanoma from healthy donors.

Figure 2

a, Diagram of ELISA of human exosomal PD-L1 in the plasma samples derived from mice harboring human melanoma xenograft. b, Levels of PD-L1 on exosomes isolated from the plasma samples of control or human WM9 melanoma xenograft-bearing nude mice as measured by ELISA (n = 10). c, Pearson correlation between the plasma level of exosomal PD-L1 and tumor burden in xenograft-bearing nude mice (n = 10). d–f, ELISA of the circulating level of exosomal PD-L1 (d), total PD-L1 (e), or EV-excluded PD-L1 (f) in healthy donors (“HD”, n = 11) and melanoma patients (“MP”, n = 44). g, ROC curve analysis for the indicated parameters in patients with metastatic melanoma compared to healthy donors. Data represent mean ± s.d. Statistical analyses were performed using two-sided unpaired t-test (b, d–f).